Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

被引：1
|
作者：
Elder, Mary J. [1 ]
Ashjian, Emily J. [2 ]
机构：
[1] Michigan Med, Pharm Innovat & Partnerships, 2500 Green Rd,Suite 100, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF PHARMACY PRACTICE | 2023年 / 36卷 / 02期
关键词：
diabetes mellitus; glucagon-like peptide-1 receptor agonist; gastric inhibitory polypeptide; G protein-coupled receptor 119 agonist; glucagon receptor agonist; RECEPTOR AGONIST; CHINESE PATIENTS; DOUBLE-BLIND; PHARMACODYNAMICS; PHARMACOKINETICS; SAFETY; METFORMIN; RG7697; SINGLE;
D O I：
10.1177/08971900211049032
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.
引用
收藏
页码：418 / 428
页数：11
相关论文
共 50 条
  • [1] Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    Nauck, M. A.
    Vardarli, I.
    Deacon, C. F.
    Holst, J. J.
    Meier, J. J.
    DIABETOLOGIA, 2011, 54 (01) : 10 - 18
  • [2] Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    M. A. Nauck
    I. Vardarli
    C. F. Deacon
    J. J. Holst
    J. J. Meier
    Diabetologia, 2011, 54 : 10 - 18
  • [3] Modern possibilities of pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1)
    Shestakova, M., V
    Vikulova, O. K.
    DIABETES MELLITUS, 2007, 10 (01): : 9 - 15
  • [4] Preserved Inhibitory Effect of Glucagon-Like Peptide-1 (GLP-1) on Glucagon Secretion in Type 2 Diabetes Mellitus
    Hare, Kristine J.
    Knop, Filip K.
    Asmar, Meena
    Larsen, Steen
    Madsbad, Sten
    Holst, Jens J.
    Vilsboll, Tina
    DIABETES, 2009, 58 : A372 - A372
  • [5] The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
    Lastya A.
    Saraswati M.R.
    Suastika K.
    BMC Research Notes, 7 (1)
  • [6] Glucagon-like peptide-1 (GLP-1) in obese subjects with and without type 2 diabetes
    Rotella, CM
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Messeri, G
    Mannucci, E
    DIABETES, 2000, 49 : A1 - A1
  • [7] The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
    Brice, Kira R.
    Tzefos, Maria K.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 13 - 24
  • [8] Normal secretion of the glucagon-like peptide-1 (GLP-1) during gestational diabetes mellitus
    Lencioni, C.
    Lupi, R.
    Resi, V.
    Bertolotto, A.
    Romero, F.
    Ghio, A.
    Volpe, L.
    Del Prato, S.
    Marchetti, P.
    Di Cianni, G.
    DIABETOLOGIA, 2009, 52 : S454 - S454
  • [9] Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): The role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress
    Bojanowska, E
    MEDICAL SCIENCE MONITOR, 2005, 11 (08): : RA271 - RA278
  • [10] A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus
    Thondam, S. K.
    Cuthbertson, D. J.
    Aditya, B. S.
    MacFarlane, I. A.
    Wilding, J. P.
    Daousi, C.
    CLINICAL ENDOCRINOLOGY, 2012, 77 (04) : 635 - 637
12345